Company Encyclopedia
View More
name
CytoDyn Inc.
CYDY.US
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation.
1.908 T
CYDY.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CytoDyn Inc. held annual shareholder meeting

    CytoDyn Inc. held its 2025 Annual Meeting of Stockholders on November 21, 2025. Stockholders elected all nominated directors, approved CBIZ CPAs P.C. as the independent accounting firm, increased authorized shares from 1.75 billion to 2.25 billion, and approved an annual advisory vote on executive compensation.

    Reuters·
    US
    CYDY
    +1.57%
    Reuters·
    US
    CYDY
    +1.57%

    CytoDyn Secures $30 Million Funding Commitment

    CytoDyn Inc. announced a Standby Equity Purchase Agreement with Yorkville Advisors Global, securing a $30 million funding commitment. This agreement allows the company to sell up to $30 million of its common stock over 36 months, providing financial flexibility for its leronlimab program. The arrangement imposes no minimum commitments, enabling CytoDyn to pursue additional financing or partnerships. Proceeds will support working capital and debt repayment. CytoDyn focuses on advancing leronlimab, a monoclonal antibody targeting the CCR5 receptor, aimed at improving patient outcomes in oncology and other diseases.

    Tip Ranks·
    US
    CYDY
    +1.57%
    Tip Ranks·
    US
    CYDY
    +1.57%

    CytoDyn Inc. SEC 10-Q Report

    CytoDyn Inc. has released its Q3 10-Q report, revealing a significant decline in financial performance. The company reported an operating loss of $4.945 million, down from a gain of $22.437 million last year, and a net loss of $5.540 million compared to a net income of $19.227 million previously. CytoDyn is focusing on the clinical development of leronlimab, facing operational challenges and seeking additional capital. The company plans to increase authorized shares to facilitate financing and is involved in various legal proceedings. The SEC and DOJ have closed their investigations into the company.

    TradingView·
    US
    CYDY
    +1.57%
    TradingView·
    US
    CYDY
    +1.57%

    CytoDyn Inc. | 10-Q: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    CYDY
    +1.57%
    LB filings·
    US
    CYDY
    +1.57%

    September 2025 Letter to Shareholders | CYDY Stock News

    CytoDyn Inc. shares progress on leronlimab as a treatment for oncology in its September 2025 letter to shareholders. The company highlights advancements in clinical trials, particularly for metastatic triple-negative breast cancer (mTNBC), and announces the appointment of Robert E. Hoffman as CFO. Positive data from recent studies suggest leronlimab's potential to enhance treatment outcomes, with plans for further clinical trials and compassionate-use programs. The company is also expanding its research into metastatic colorectal cancer (mCRC).

    StockTitan·
    US
    CYDY
    +1.57%
    StockTitan·
    US
    CYDY
    +1.57%